Related Experiment Video
Updated: Feb 24, 2026
10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
16.4K
Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease
Ingrid H C H M Philippens1,2, Jacqueline A Wubben2, Raymond A P Vanwersch1
1Animal Science Department Biomedical Primate Research Centre (BPRC) P.O. Box 3306 Rijswijk 2280 GH the Netherlands.
Annals of Clinical and Translational Neurology
|August 17, 2017
Summary
Sensorimotor rhythm neurofeedback training, a brain stimulation technique, effectively reduced Parkinson's disease symptoms in primates. This therapy may also improve L-DOPA treatment outcomes and reduce side effects.
Area of Science:
- Neuroscience
- Neurology
- Biomedical Engineering
Background:
- Neurofeedback shows potential for enhancing brain compensatory mechanisms.
- Sensorimotor rhythm neurofeedback is a promising intervention for Parkinson's disease.
- Parkinson's disease is characterized by motor deficits and L-DOPA treatment fluctuations.
Purpose of the Study:
- To investigate the efficacy of sensorimotor rhythm neurofeedback in an animal model of Parkinson's disease.
- To assess the impact of neurofeedback on MPTP-induced parkinsonian symptoms.
- To evaluate neurofeedback's effect on L-DOPA treatment response in Parkinson's disease.
Main Methods:
- A placebo-controlled study was conducted using parkinsonian nonhuman primates.
- Electroencephalography (EEG)-based sensorimotor rhythm neurofeedback was administered.
- Parkinsonian symptoms and L-DOPA treatment scores (ON/OFF) were measured.
Main Results:
- Sensorimotor rhythm neurofeedback significantly reduced MPTP-induced parkinsonian symptoms.
- Neurofeedback improved both ON and OFF medication scores during L-DOPA treatment.
- No adverse effects were reported, suggesting a favorable safety profile.
Conclusions:
- Sensorimotor rhythm neurofeedback is a viable therapeutic approach for Parkinson's disease.
- This neurofeedback training may serve as an effective adjunct therapy to L-DOPA.
- Further clinical development is warranted to explore its potential in reducing L-DOPA side effects.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K